Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer
BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a new drug application (NDA) of ... Read More
Inozyme Pharma acquires Alexion’s ENPP1 gene deficiency program assets
Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies for an undisclosed price. The acquisition is ... Read More
Topcon Healthcare acquires Henson perimeter business of Elektron Eye Technology
Topcon Healthcare, a US ophthalmic device manufacturer, has acquired the Henson perimeter business of UK-based Elektron Eye Technology (EET) for an undisclosed price. The range ... Read More
ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca
Russian pharma company R-Pharm has reportedly signed an agreement with AstraZeneca for manufacturing the ChAdOx1 nCoV-19 vaccine being developed by the latter in collaboration with ... Read More
ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca
Russian pharma company R-Pharm has reportedly signed an agreement with AstraZeneca for manufacturing the ChAdOx1 nCoV-19 vaccine being developed by the latter in collaboration with ... Read More
Ascentage Pharma gets FDA ODD for APG-2575 in Waldenström macroglobulinemia
Ascentage Pharma has been granted orphan drug designation (ODD) for its Bcl-2 inhibitor APG-2575 from the US Food and Drug Administration (FDA) for the treatment ... Read More
Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More
Galera Therapeutics enrolls patients for pancreatic cancer trial of GC4419
Galera Therapeutics said that it has wrapped up enrollment of patients for its phase 1b/2a safety and anti-cancer efficacy clinical trial of the combination of ... Read More
BNT162b1 and BNT162b2 Covid-19 vaccine candidates get FDA fast track status
Pfizer and BioNTech said that BNT162b1 and BNT162b2, two vaccine candidates developed to give protection against the SARS-CoV-2 virus have been given the fast track ... Read More
Moderna, Rovi to collaborate on fill-finish manufacturing of mRNA-1273
Moderna and Laboratorios Farmacéuticos Rovi have entered into a collaboration for large-scale, commercial fill-finish manufacturing of mRNA-1273, the former's mRNA vaccine candidate against COVID-19, at ... Read More